Stay updated on Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page.

Latest updates to the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page
- Check2 days agoChange DetectedStudy status changed from 'Active, not recruiting' to 'Completed'. The page now lists a study completion date (2025-08-15) and an estimated last update posted date (2025-12) in the status section.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedLocations section now lists new sites in Illinois and New York and the revision version updated to v3.3.3. Older Illinois/New York locations and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.3%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedUpdated revision from v3.3.1 to v3.3.2; no visible changes to study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page shows a minor revision update from v3.2.0 to v3.3.1, with no changes to study content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRemoved the banner about a lapse in government funding and related operating status notices. The study details and other trial information remain unchanged.SummaryDifference0.4%

- Check67 days agoChange DetectedNo substantive changes detected between the two screenshots; the study details appear unchanged (title, objectives, eligibility criteria, and outcomes), with only minor formatting/layout differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page.